In a report issued on July 9, Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (ATNM), with a price target of $1.50. The company’s shares closed yesterday at $0.24, close to its 52-week low of $0.23.
According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -18.4% and a 26.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Aridis Pharmaceuticals Inc, and Achieve Life Sciences Inc.
Actinium Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $3.13.
See today’s analyst top recommended stocks >>
The company has a one-year high of $0.87 and a one-year low of $0.23. Currently, Actinium Pharmaceuticals has an average volume of 1.57M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.
